## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

wasnington, D.	C. 2054

	OMB APPROVAL									
	OMB Number: 3235-028									
	Estimated average burden									
l	hours ner resnonse.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Lakebovite Ava				2. Issuer Name <b>and</b> Ticker or Trading Symbol Adicet Bio, Inc. [ ACET ]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Jakobovits Aya</u>				ŀ							X	Director		10% Owner	
(Last)	,	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/14/2023						Officer ( below)	give title	Other (sp below)	pecify	
	CET BIO,				4. If Am	endment	, Date of	Original Filed	(Month/Day/	Year)		lividual or Jo	oint/Group Filin	g (Check Appl	icable
200 BER	KELEY ST	FREET, 19TH F	LOOR								Line)	Form file	ed by One Rep	orting Person	
(Street)											Form filed by More than One Reporting				
BOSTON MA 02116		ŀ	Dula 40h5 4(a) Transaction Indication							Person					
(City) (State) (Zip)			Rule 10b5-1(c) Transaction Indication												
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Та	ble I - Non-D	Deriva	tive S	ecuriti	es Acq	uired, Dis	posed of	, or Bene	eficially	Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D		ate	Execution Date,		3. Transaction Code (Instr. 8)			(A) or 3, 4 and 5)	5. Amount Securities Beneficial Owned Fo	For lly (D)	n: Direct II or Indirect B	7. Nature of ndirect Beneficial Ownership			
						(monangay) road)		Code V	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 ar	on(s)	(,, ,	Instr. 4)
			Table II - De					ired, Disp options, o				Owned	,	,	1
1. Title of	2.	3. Transaction	3A. Deemed	4.	,	5. Num		6. Date Exerc		7. Title and		8. Price of	9. Number of	10.	11. Nature
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security		Execution Date, if any	Code	ansaction Derivative Securities		Expiration Date (Month/Day/Year) of Securities Underlying Derivative Sec (Instr. 3 and 4)		g Security	Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)		
											Amount or Number		Transaction(s)	'	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	of Shares				
Stock Option (Right to Buy)	\$16.11	08/14/2023		D <sup>(1)</sup>			30,000	(2)	09/16/2030	Common Stock	30,000	\$0.00 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$2.14 <sup>(3)</sup>	08/14/2023		A <sup>(1)</sup>		30,000		(2)	09/16/2030	Common Stock	30,000	\$0.00 <sup>(1)</sup>	30,000	D	
Stock Option (Right to Buy)	\$15.93	08/14/2023		D <sup>(1)</sup>			18,500	(4)	04/29/2031	Common Stock	18,500	\$0.00 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$2.14 <sup>(3)</sup>	08/14/2023		A <sup>(1)</sup>		18,500		(4)	04/29/2031	Common Stock	18,500	\$0.00 <sup>(1)</sup>	18,500	D	
Stock Option (Right to Buy)	\$11.49	08/14/2023		D <sup>(1)</sup>			18,500	(4)	06/01/2032	Common Stock	18,500	\$0.00 <sup>(1)</sup>	0	D	
Stock Option (Right to Buy)	\$2.14 <sup>(3)</sup>	08/14/2023		A <sup>(1)</sup>		18,500		(4)	06/01/2032	Common Stock	18,500	\$0.00 <sup>(1)</sup>	18,500	D	
Stock Option (Right to Buy)	\$5.195	08/14/2023		D <sup>(1)</sup>			26,400	(5)	05/31/2033	Common Stock	26,400	\$0.00 <sup>(1)</sup>	0	D	
Stock Option (Right to	\$2.14 <sup>(3)</sup>	08/14/2023		A <sup>(1)</sup>		26,400		(5)	05/31/2033	Common Stock	26,400	\$0.00 <sup>(1)</sup>	26,400	D	

## Explanation of Responses:

- 1. On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- 2. The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
- 3. The exercise price of the option is \$2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the
- ${\bf 4.}\ The\ shares\ subject\ to\ this\ option\ are\ fully\ vested\ and\ exercisable\ as\ of\ the\ date\ hereof.$
- 5. The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

## Remarks:

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.